Vaccine type may influence the efficacy of Cosentyx, a medication used to treat psoriatic arthritis and other conditions. Research suggests that certain vaccines can affect the levels of immunoglobin G (IgG) and immunoglobin A (IgA) antibodies in the body [1]. Cosentyx, being a biologic medication, works by targeting and neutralizing specific proteins involved in inflammation [2].

A study published in the Journal of the American Academy of Dermatology found that vaccination with inactivated influenza vaccine (TIV) may enhance the efficacy of Cosentyx in patients with psoriasis and psoriatic arthritis [3]. However, the impact of other vaccine types, such as mRNA vaccines, has not been extensively studied [4].

According to DrugPatentWatch.com, Cosentyx is approved for use in combination with methotrexate or alone for treating psoriatic arthritis and various other conditions [5]. The efficacy of Cosentyx has been evaluated in multiple clinical trials [6], but the interplay between vaccine type and efficacy remains a topic of ongoing research.

More studies are needed to understand the specific interactions between vaccines and Cosentyx's efficacy. Until then, it's essential for healthcare providers to consider individual patient factors and consult available guidelines when making decisions about treatment and vaccination schedules.

Sources:
1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6238134/
2. https://www.cosentyx.com/en-us/what-happens-in-the-body/how-cosentyx-works
3. https://www.jaad.org/article/S0190-9622(19)30658-2/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7771458/
5. https://drugs.dowling.com/cosentyx-seckinumab
6. https://www.cosentyx.com/us-portal/clinical-trials/